Veloxis, Athena enter alliance for AtorFen drug
AtorFen contains the lowest fully effective dose of fenofibrate and is a combination of two dyslipidemia treatments in one tablet. The data from AtorFen’s study showed improvements in
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The Quad contains four Gilead compounds in a complete once-daily, single-tablet regimen that include elvitegravir; cobicistat, a boosting agent that enables elvitegravir once-daily dosing; and Truvada(R) (emtricitabine/tenofovir disoproxil
The ingredients by SourceOne comprise specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, TocoSource Palm Tocotrienols, and VESIsorb (which is designed to enhance bioavailability of a variety